Drug Profile
Research programme: serotonin 4 receptor antagonists - Serodus Pharmaceuticals
Alternative Names: DDL 60xx; SER-120Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Serodus
- Developer Drug Discovery Laboratory; Serodus; University of Oslo
- Class Small molecules
- Mechanism of Action Serotonin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atrial fibrillation; Cardiovascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atrial-fibrillation in Norway (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Norway
- 09 Oct 2013 Preclinical trials in Atrial fibrillation in Norway (Parenteral) before October 2013